Saudi Pharmaceutical Industries and Medical Appliances Past Earnings Performance
Past criteria checks 2/6
Saudi Pharmaceutical Industries and Medical Appliances has been growing earnings at an average annual rate of 27.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 0.8% per year. Saudi Pharmaceutical Industries and Medical Appliances's return on equity is 2.3%, and it has net margins of 1.4%.
Key information
27.9%
Earnings growth rate
27.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 0.8% |
| Return on equity | 2.3% |
| Net Margin | 1.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Solid Earnings May Rest On Weak Foundations
Nov 24
Investors Still Aren't Entirely Convinced By Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Revenues Despite 27% Price Jump
Sep 05Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Not Lagging Industry On Growth Or Pricing
Mar 21Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Worth ر.س38.1 Based On Its Intrinsic Value?
Jun 26Is There An Opportunity With Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) 20% Undervaluation?
Mar 14Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Intrinsic Value Is Potentially 52% Above Its Share Price
Aug 02Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Dividend Is Being Reduced To ر.س0.60
May 19One Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) Analyst Just Made A Major Cut To Next Year's Estimates
May 12A Look At The Fair Value Of Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070)
Feb 20Saudi Pharmaceutical Industries and Medical Appliances' (TADAWUL:2070) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 18Does It Make Sense To Buy Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) For Its Yield?
Mar 30Should Saudi Pharmaceutical Industries and Medical Appliances (TADAWUL:2070) Be Disappointed With Their 50% Profit?
Feb 23What You Need To Know About Saudi Pharmaceutical Industries and Medical Appliances Corporation's (TADAWUL:2070) Investor Composition
Jan 19
Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (TADAWUL:2070) At Risk Of Cutting Its Dividend?
Dec 16Revenue & Expenses Breakdown
How Saudi Pharmaceutical Industries and Medical Appliances makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,628 | 23 | 622 | 54 |
| 30 Jun 24 | 1,562 | -18 | 590 | 48 |
| 31 Mar 24 | 1,597 | -40 | 613 | 46 |
| 31 Dec 23 | 1,653 | -20 | 616 | 41 |
| 30 Sep 23 | 1,686 | -76 | 659 | 47 |
| 30 Jun 23 | 1,662 | -78 | 660 | 51 |
| 31 Mar 23 | 1,564 | -142 | 673 | 47 |
| 31 Dec 22 | 1,422 | -152 | 631 | 43 |
| 30 Sep 22 | 1,425 | -94 | 589 | 51 |
| 30 Jun 22 | 1,379 | -42 | 563 | 41 |
| 31 Mar 22 | 1,394 | 38 | 547 | 36 |
| 31 Dec 21 | 1,460 | 30 | 537 | 29 |
| 30 Sep 21 | 1,471 | 57 | 527 | 14 |
| 30 Jun 21 | 1,532 | 117 | 519 | 20 |
| 31 Mar 21 | 1,534 | 110 | 513 | 20 |
| 31 Dec 20 | 1,555 | 130 | 532 | 20 |
| 30 Sep 20 | 1,521 | -114 | 611 | 1 |
| 30 Jun 20 | 1,491 | -153 | 611 | 1 |
| 31 Mar 20 | 1,518 | -365 | 657 | 7 |
| 31 Dec 19 | 1,487 | -434 | 653 | 13 |
| 30 Sep 19 | 1,743 | -163 | 586 | 40 |
| 30 Jun 19 | 1,626 | -204 | 594 | 40 |
| 31 Mar 19 | 1,566 | 6 | 551 | 39 |
| 31 Dec 18 | 1,503 | 74 | 541 | 40 |
| 30 Sep 18 | 1,313 | 66 | 517 | 34 |
| 30 Jun 18 | 1,366 | 61 | 500 | 37 |
| 31 Mar 18 | 1,375 | 85 | 459 | 39 |
| 31 Dec 17 | 1,386 | 139 | 488 | 37 |
| 30 Sep 17 | 1,315 | 274 | 589 | 36 |
| 30 Jun 17 | 1,295 | 296 | 605 | 31 |
| 31 Mar 17 | 1,329 | 289 | 654 | 31 |
| 31 Dec 16 | 1,259 | 277 | 633 | 31 |
| 30 Sep 16 | 1,448 | 124 | 563 | 48 |
| 30 Jun 16 | 1,499 | 149 | 544 | 41 |
| 31 Mar 16 | 1,595 | 347 | 559 | 33 |
| 31 Dec 15 | 1,705 | 357 | 561 | 25 |
| 30 Sep 15 | 1,604 | 457 | 574 | 0 |
| 30 Jun 15 | 1,562 | 465 | 570 | 0 |
| 31 Mar 15 | 1,500 | 325 | 558 | 0 |
| 31 Dec 14 | 1,470 | 317 | 552 | 0 |
| 30 Sep 14 | 1,424 | 283 | 547 | 0 |
| 30 Jun 14 | 1,381 | 279 | 528 | 0 |
| 31 Mar 14 | 1,351 | 295 | 516 | 0 |
| 31 Dec 13 | 1,311 | 267 | 502 | 0 |
Quality Earnings: 2070 has a large one-off gain of SAR24.1M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 2070 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2070 has become profitable over the past 5 years, growing earnings by 27.9% per year.
Accelerating Growth: 2070 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 2070 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.6%).
Return on Equity
High ROE: 2070's Return on Equity (2.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 20:57 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Saudi Pharmaceutical Industries and Medical Appliances Corporation is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Abdullah Alawi | Aljazira Capital Company |
| Madhu Appissa | Al Rajhi Capital |
| Aleksandar Stojanovski | Deutsche Bank |